预约演示
更新于：2025-11-08
Naftopidil
萘哌地尔
更新于：2025-11-08
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H28N2O3 |
InChIKeyHRRBJVNMSRJFHQ-UHFFFAOYSA-N |
CAS号57149-07-2 |
关联
19
项与 萘哌地尔 相关的临床试验JPRN-jRCTs031180176
A prospective randomized controlled study on Suppression of Prostate cancer by Naftopidil - SNAP study
CTR20160675
评估KT-611片和那妥于空腹和餐后状态下中国健康男性的随机、开放、单剂量、两阶段、两序列、交叉生物等效性研究
CTR20160671
评估KT-611片和司坦迪于空腹和餐后状态下中国健康男性的随机、开放、单剂量、两阶段、两序列、交叉生物等效性研究
100 项与 萘哌地尔 相关的临床结果
登录后查看更多信息
100 项与 萘哌地尔 相关的转化医学
登录后查看更多信息
100 项与 萘哌地尔 相关的专利（医药）
登录后查看更多信息
392
项与 萘哌地尔 相关的文献（医药）2025-06-17ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Excited‐State Basicity Diverts the Site‐Selectivity of Aromatic Deuteration: Application to the Late‐Stage Labeling of Pharmaceuticals
Article
作者: Ruffoni, Alessandro ; Corpas, Javier ; Rivera‐Chao, Eva ; Derdau, Volker ; Leonori, Daniele ; Lonardi, Giovanni
Abstract:
Isotope labeling, particularly with deuterium (2H), plays a critical role in drug discovery due to its ease of incorporation and its potential to switch unwanted metabolic transformations. Deuterium incorporation can enhance drug stability, affect pharmacokinetics, and alter metabolism pathways. Current deuterium labeling methods focus on hydrogen isotope exchange (HIE), and typically rely on the use of transition metal catalysis. Herein, we present a metal‐free approach for aromatic HIE, utilizing photoexcitation in deuterated hexafluoroisopropanol (HFIP‐d1). By exploiting the enhanced basicity of excited‐state aromatics, this method achieves selective deuteration at positions often inaccessible by traditional methods. The approach is efficient and was demonstrated across a broad number of complex drug molecules. Transient absorption spectroscopy confirms the formation of deuterated arenium ions.
2025-04-01INTERNATIONAL JOURNAL OF UROLOGY
α1‐Blockers as a risk factor for hypotension in combination with oral 5‐aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer
Article
作者: Minagawa, Tomonori ; Suzuki, Chihiro ; Hiragata, Shiro ; Kinebuchi, Yoshiaki ; Onuma, Hiromu
This study analyzed the adverse events associated with 5-ALA in PDD and assessed the preoperative use of a1-blockers as a risk factor for hypotension.A total of 203 patients (161 male and 42 female) were enrolled in this study.Five-ALA were received 20 mg/kg. Patient age ranged from 45 to 96 years, with a mean age of 73.3 years.RASI were regularly used to 72 patients (31.0%), and Ca-blockers to 69 patients (34.0%).Antihypertensive medication was taken on the day of surgery among 58 patients (28.6%) as followed by the discretion of the anesthesiologists.A1-blockers were regularly used to 25 patients (12.3%).The details of a1-blockers were as follows: 16 for tamsulosin, 2 for naftopidil, and 7 for silodosin.The duration of medication ranged from 2 mo to 16 years, with a median of 2 years.Spinal anesthesia was performed on 159 patients (78.3%).Hypotension was intraoperatively observed in 63 patients (30.9%), nausea in 62 patients (30.4%), and decreased percutaneous oxygen saturation of <90% in 10 patients (12.3%).Postoperative hypotension was revealed among three of the enrolled patients, whereas preoperative hypotension was not.Table 1 summarizes the results of risk factor anal. for a decrease in SBP during PDD-assisted TURBT.Both analyses revealed general anesthesia, regular use of angiotensin receptor blocker (ARB) combination medicine, Ca-blockers, and preoperative a1-blockers as significant risk factors for hypotension in PDD-assisted TURBT.
2025-01-01CRYSTAL GROWTH & DESIGN
Organic Crystals: Comprehensive Understanding of Proton States of Naftopidil Salts via XPS
作者: Addala, Uma Mahesh ; Dandela, Rambabu ; Tothadi, Srinu
In this study, 18 Naftopidil (NFPD) binary salts were synthesized and then analyzed via XPS.Among these salts, nine known binary salts were initially investigated via SCXRD, where in every binary complex, the carboxylic acid (-COOH) proton is transferred to N of naftopidil.Afterward, these nine naftopidil salts were examined via XPS, where N 1s binding energies of salts showed a significant binding energy shift (2.1 to 2.6 eV) compared to neutral N 1s binding energies of naftopidil.Later, nine novel complexes were synthesized and explored via XPS.Interestingly, these new crystalline materials also manifest considerable N 1s binding energy shifts (1.9 to 2.4 eV) compared to the neutral N 1s binding energies of naftopidil.After a detailed evaluation of XPS exptl. results, new complexes were predicted as naftopidil salts, and SCXRD studies further confirmed these results.Moreover, all these crystalline materials were also characterized by Powder X-ray diffraction (PXRD) and Fourier Transform IR Spectroscopy (FT-IR).Intermol. interactions are further studied by Hirshfeld Surface Anal. (HSA).
100 项与 萘哌地尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 排尿困难 | 日本 | - | 1998-12-25 |
| 前列腺增生症 | 日本 | - | 1998-12-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 医疗器械不适 | 临床3期 | 美国 | 2014-05-01 | |
| 输尿管结石病 | 临床3期 | 美国 | 2014-05-01 | |
| 术后疼痛 | 临床3期 | 韩国 | 2013-10-25 | |
| 神经性膀胱功能障碍 | 临床2期 | 日本 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用